Equillium, Inc. (EQ): Price and Financial Metrics
GET POWR RATINGS... FREE!
EQ Stock Price Chart Interactive Chart >
EQ Price/Volume Stats
|Current price||$2.49||52-week high||$7.75|
|Prev. close||$2.48||52-week low||$1.82|
|Day high||$2.55||Avg. volume||45,110|
|50-day MA||$2.83||Dividend yield||N/A|
|200-day MA||$4.44||Market Cap||85.35M|
Equillium, Inc. (EQ) Company Bio
Equillium Inc. is leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is based in La Jolla, California.
Most Popular Stories View All
EQ Latest News Stream
|Loading, please wait...|
EQ Latest Social Stream
View Full EQ Social Stream
Latest EQ News From Around the Web
Below are the latest news stories about Equillium Inc that investors may wish to consider to help them evaluate EQ as an investment opportunity.
Equillium Inc (NASDAQ: EQ ), with only one asset in its pipeline , is expanding its drug development efforts via the acquisition of Bioniz Therapeutics . The deal, worth approximately $330 million, gives the biotech access to three therapeutics. Equillium will buy Bioniz in an all-stock deal for around 5.69 million shares and up to $57.5 million in development biobucks. The deal … Full story available on Benzinga.com
Equillium (EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront…
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
LA JOLLA, Calif., February 16, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. T
LA JOLLA, Calif., February 15, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.
Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythemat...
EQ Price Returns